Beta Bionics, Inc. (BBNX) shares plunged 32.79 percent on Friday, falling $10.49 to $21.50, possibly reacting to the company's preliminary, unaudited fourth-quarter 2025 financial results released yesterday.
The stock was trading at $21.50, sharply lower from its previous close of $31.99 on the Nasdaq. Shares opened at $22.75 and traded between $20.03 and $23.92 during the session. Trading volume surged to about 4.53 million shares, well above the average volume of roughly 777,000 shares.
Earlier, Beta Bionics shared that they expect their net sales for the fourth quarter of 2025 to hit at least $32 million. They estimate that net sales from their Durable Medical Equipment channel will be around $22.3 million, while sales from the Pharmacy Benefit Plan channel should hit at least $9.7 million, which is more than triple what the company saw last year.
Beta Bionics has traded within a 52-week range of $8.89 to $32.71.
For comments and feedback contact: editorial@rttnews.com
Business News
September 04, 2026 15:08 ET The job report and foreign trade data were the main economic news from the U.S. in the first week of September. Elsewhere in North America, the Canadian central bank announced its latest policy decision. Inflation data from Eurozone was the highlight in Europe. The latest interest rate decision by the Reserve Bank of New Zealand drew attention in Asia.